UREMIC CALCIPHYLAXIS UNDER THE CALCIMIMETIC CINACALCET

• Autor(a) principal: Ramos, Leonor
• Data de Publicação: 2015
• Outros Autores: Coutinho, I., Linhares, L., Brites, M. M., Cardoso, José Carlos, Tellechea, Óscar, Gonçalo, Margarida
• Tipo de documento: Artigo
• Idioma: por
• Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
• Texto Completo: https://doi.org/10.29021/spdv.72.4.328
• topic: Calciphylaxis; Cinacalcet; Hyperparathyroidism; Calcifilaxia; Cinacalcet; Hiperparatiroidismo

Uremic calciphylaxis is a rare but serious complication of dialysis patients. Its pathogenesis is not completely understood, although many risk factors have been identified, such as hyperparathyroidism. Cinacalcet (a calcimimetic agent) is used to keep calcium, phosphorus and PTH within the normal range. A 72-year old female patient, under hemodialysis for 15 years with hyperphosphatemia, normocalcemia and hyperparathyroidism despite therapy with cinacalcet and sevelamer, presented with several painful ulcerated lesions of the right leg, with a geographical configuration, central necrotic surface and hemorrhagic borders that progressed for 6 weeks. Cutaneous biopsy revealed vascular deposits of calcium in deep dermal and hypodermal vessels, confirming the clinical diagnosis of calciphylaxis. The necrotic borders of the ulcer improved when cinacalcet and sevelamer were administered in maximum doses. However, the patient passed away in consequence of comorbidities. We report a case in which cinacalcet was ineffective in controlling the phosphate and calcium abnormalities in an hemodialysis patient and, consequently, his cutaneous lesions.